Inventor
MADIYALAKAN RAGUPATHY
CA16 patents
⚠️ This page may combine multiple inventors who share the name “MADIYALAKAN RAGUPATHY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALTAREX INC
4 patentsUS6716966B1Apr 6, 2004
Therapeutic binding agents against MUC-1 antigen and methods for their use
ALTAREX INC56 citations94
US6241985B1Jun 5, 2001
Method and composition for reconforming multi-epitopic antigens to initiate an immune response
ALTAREX INC29 citations89
US6086873AJul 11, 2000
Therapeutic composition and method of treatment
ALTAREX INC10 citations69
US7361346B1Apr 22, 2008
Therapeutic compositions that produce an immune response
ALTAREX INC2 citations55
ALTAREX MEDICAL CORP
4 patentsUS7147850B2Dec 12, 2006
Therapeutic binding agents against MUC-1 antigen and methods for their use
ALTAREX MEDICAL CORP19 citations91
US6881405B2Apr 19, 2005
Reagents and methods for inducing an immune response to prostate specific antigen
ALTAREX MEDICAL CORP45 citations91
US7318921B2Jan 15, 2008
Therapeutic compositions that alter the immune response
ALTAREX MEDICAL CORP3 citations59
US7579445B2Aug 25, 2009
Reagents and methods for inducing an immune response to prostate specific antigen
ALTAREX MEDICAL CORP0 citations48
ONCOQUEST INC
4 patentsUS11351255B2Jun 7, 2022
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
ONCOQUEST INC0 citations58
US10975163B2Apr 13, 2021
Methods of increasing delivery of anti-cancer agents to targets
ONCOQUEST INC0 citations58
US10537636B2Jan 21, 2020
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
ONCOQUEST INC1 citations58
US10392444B2Aug 27, 2019
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
ONCOQUEST INC0 citations48